PFS & INJECTABLE DRUG DEVICES

EUROPE

SPEAKER INTERVIEW

Javad Jabbari,
Director Regulatory Affairs RA Device and Combination Products
Ascendis Pharma

About you – What is your role, and what perspective will you bring to the PFS & Injectable Drug Delivery Europe Conference?

I'm Director of Global Regulatory Affairs (Medical Devices & Combination Products). I bring a cross-functional EU–US lens on PFS and injectables—anchored in Article 117/MDR, FDA 21 CFR Part 4, ISO 11608, UDI/labeling, and design-to-risk control—linking development, manufacturing controls, and lifecycle compliance. I have extensive experiences with medical devices and combination products from R&D, QA and RA perspective.

The injectable drug delivery landscape is evolving rapidly. What do you see as the most exciting innovations or breakthroughs in the past year?

- Rapid progress in large-volume/wearable injectors for high-viscosity biologics.
- Silicone-minimized/silicone-free PFS systems and improved coatings to reduce particles and interactions.
- More modular auto-injector platforms and early, pragmatic connectivity that supports adherence without burdening users.
- Design-for-sustainability moving from slideware to concrete component/packaging choices.

PFS & INJECTABLE DRUG DEVICES

EUROPE

SPEAKER INTERVIEW

What major shifts or challenges do you anticipate in the pre-filled syringes and injectable drug delivery space over the next few years?

More focus on the combination product as whole, instead of silo-based approach, tighter sustainability and packaging expectations, NB/Article-117 scrutiny on device evidence, harmonizing UDI/NDC for combos, cyber-secure connectivity, and supply-chain/material changes impacting PFS performance and biocompatibility.

How do you see emerging technologies (e.g. sustainable materials, digital health integration ect.) shaping the future of injectable drug delivery?

Connected devices & combination products will integrate with digital therapeutics and PV; data standards will enable dose-event traceability and outcome-based contracting; reusable platforms will gain share in chronic care, and sustainable polymers/COC-COP and circular design will become baseline;

What are you most looking forward to at the 18th Annual PFS & Injectable Drug Delivery Conference? Are there any sessions or speakers you're particularly excited about?

The parallel streams on Sustainability in Medical Devices and Digital Health & Connected Devices, plus exchanges with speakers from TÜV SÜD (Article 117/NB opinions), GSK (packaging sustainability), and AstraZeneca (delivery tech strategy).
